Aldevron Breakthrough Blog

Perspectives: Hold on Tight for the Ride

A crazy, mixed-up world of cell & gene therapy in 2023

News concerning cell and gene therapy (CGT) may make you feel like you are on a rollercoaster. The ride moves very quickly with a lot of ups and downs, plus a few unexpected turns. As we move through 2023, excitement for CGT remains high, but there are lingering concerns about manufacturing and the ability of health care systems to keep up with the science.

Read More

An evolution at TIDES

mRNA joins the mix

In the past, the TIDES USA conference event has been focused on oligonucleotide and peptide therapeutics, providing information on development trends and technologies for those industry segments. That is changing now, with an additional focus on mRNA therapeutics coming into the mix. 

Read More

When Demand Gets Tough, Expansion Gets Going

Ongoing growth in CGT capacity

As the era of genomic medicine gains speed with the innovation of new technologies, we are at the forefront of genetic tools that can prevent, treat, or cure human diseases. It’s an exciting time, as during this early stage in developing new biological drug products, academics and industry are working closely to optimize cell and gene therapies (CGT) for a range of diseases. 

Read More

Advancing through Disruption

Achieving advancement in ATMP regulation through disruptive innovation of European healthcare systems

Partnerships and transformation are a large part of our evolving biotech landscape. Not surprisingly, they were two common themes at this year’s Meeting on the Med in Barcelona.  As an example, attendees discussed how the lack of harmonization across EU member states has led to fragmented access to advanced therapy medicinal products (ATMPs), which varies from country to country. Chris Fox, president of Novartis Gene Therapies, used her company’s product, ZOLGENSMA®, as an example. It’s approved for use in 48 countries but is only accessible in 35. 

Read More


The most important tool to support client success through lead-time reductions

Successful – for both Aldevron and our clients. That is how I would describe Aldevron’s first Shingijutsu Kaizen event and the first Danaher CEO Kaizen event of 2023, held the week of April 10. Not only did the efforts surpass all expectations but it surpassed deliverable goals--success!

Read More

Streamlining the Drug Development Process

Aldevron expands mRNA  production capability

After years of service providers becoming more specialized, we’re now seeing a reversal in that trend. Enterprise offerings and solutions are on the rise, from consumer offerings to huge corporate deals. We can attribute this growth to an increased demand for simplicity of transactions, clear accountability, and building a win-win situation for both parties. 

Read More